Affordable Point-of-Care Diagnostics Cholestech's flagship systems provide rapid and cost-effective diagnostic testing for cholesterol, blood glucose, and related biomarkers, positioning them as a key solution for clinics seeking quick, reliable results at the point of care.

Growth Potential With annual revenues estimated between $10 million and $25 million and a focused product portfolio, Cholestech presents opportunities for expanding sales by increasing adoption in outpatient and primary care settings.

Industry-Leading Technology The company's advanced diagnostic systems, such as Cholestech LDX and GDX, offer a competitive edge that can be leveraged to attract healthcare providers looking for accurate and fast testing solutions.

Smaller, Specialized Player As a mid-sized manufacturer with 51-200 employees, Cholestech may benefit from strategic partnerships and targeted outreach to niche markets within the broader diagnostic industry.

Market Trends Engagement Given the increasing emphasis on immediate testing and point-of-care diagnostics in healthcare, Cholestech is well-positioned to capitalize on the growing demand for portable, rapid testing solutions across diverse care environments.